Aleta Biotherapeutics Reports First Patient Dosing with ALETA-001 in P-I/II Study for Treating Relapsed/Refractory B-Cell Malignancies
Shots:
- Aleta has dosed first patient with ALETA-001 in the P-I/II study, being developed in collaboration with Cancer Research UK’s Director of Drug Development
- The P-I/II dose-expansion study investigates the safety, efficacy, tolerability and PK/PD effects of ALETA-001 monotx. in patients who have previously received and failed treatment with available CD19-targeting CAR T-cell therapies
- ALETA-001 consists of CD19 target protein associated with CD20 Ab domain to increase the density of CD19 antigen & restoring the expression of CD19 on the cancer cells. This enables previously administered CD19-directed CAR T-cell therapies to identify CD19+/CD20+ cancer cells for their destruction
Ref: Aleta Biotherapeutics | Image: Aleta Biotherapeutics
Related News:- Innocare Announces the Results of P-II Study for TYK2 Inhibitor ICP-332 in Patients with Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
